Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Hen Egg Allergy
In brief
To determine the efficacy and safety of AR201 in a characterized oral desensitization immunotherapy (CODIT™) regimen in hen egg-allergic subjects aged 4 to 26 years, inclusive.
Key facts
- Study ID
- NCT04056299
- Run by
- Aimmune Therapeutics, Inc.
- People needed
- 15
- Starts
- 2019-08-20
- Expected to finish
- 2020-12-28
- Last updated by the study team
- 2022-03-10
Who can join
Age: 4 and older, up to 26. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arkansas Children's Hospital — Little Rock, Arkansas, United States
- Peninsula Research Associates — Rolling Hills Estates, California, United States
- Allergy & Asthma Medical Group and Research Center, A.P.C — San Diego, California, United States
- Allergy & Asthma Associates of Santa Clara Valley Research Center — San Jose, California, United States
- Allergy and Asthma Clinical Research dba Bay Area Allergy — Walnut Creek, California, United States
- Atlanta Allergy & Asthma Clinic, PA — Marietta, Georgia, United States
- Idaho Allergy LLC, dba Idaho Allergy and Research — Eagle, Idaho, United States
- Chesapeake Clinical Research, Inc. — White Marsh, Maryland, United States
- Clinical Research Institute Inc — Minneapolis, Minnesota, United States
- Atlantic Research Center, LLC — Ocean City, New Jersey, United States
- Seattle Allergy & Asthma Research Institute dba ASTHMA, Inc. Clinical Research Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.